Hengrui Pharmaceutical announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-3095 tablets and will conduct clinical trials in the near future. HRS-3095 tablets are small molecule compounds independently developed by the company that target immune cells, and have a good therapeutic effect on allergic diseases. Preclinical data showed that HRS-3095 can effectively improve skin allergy symptoms in mice. According to inquiries, there are currently no drugs with the same target approved for marketing at home or abroad for CSU indications. Up to now, HRS-3095 film-related projects have invested a total of about 16.03 million yuan in R&D.

Zhitongcaijing · 09/23/2025 09:41
Hengrui Pharmaceutical announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-3095 tablets and will conduct clinical trials in the near future. HRS-3095 tablets are small molecule compounds independently developed by the company that target immune cells, and have a good therapeutic effect on allergic diseases. Preclinical data showed that HRS-3095 can effectively improve skin allergy symptoms in mice. According to inquiries, there are currently no drugs with the same target approved for marketing at home or abroad for CSU indications. Up to now, HRS-3095 film-related projects have invested a total of about 16.03 million yuan in R&D.